Company intelligence / Profile preview

Delsona Therapeutics

New York City, New York, United Statesdelsona.com ↗

Ownership: Private
Development stage: Other

Overview

Delsona has initiated clinical trials using its UltraNav platform for noninvasive BBB opening in pediatric brain cancer and Alzheimer’s patients. Preclinical models have shown enhanced drug uptake into the brain with promising efficacy signals. Safety data from animal studies and early human trials are encouraging. The technology is MRI-free, portable, and can be used with any therapeutic modality without reformulation. Two clinical trials completed as of mid-2023; four more planned or underway across neuro-oncology and neurodegeneration indications.

Therapeutic areas: NeurologyOncology
Modalities: DeviceDrug delivery technologySmall moleculeAntibodyGene therapyCell therapyProteinNucleotide therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Delsona Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delsona Therapeutics.

Explore the full profile